Loading clinical trials...

Evolution of Lymphocyte Populations Under Biotherapy in Inflammatory Bowel Disease | Clinical Trials | Clareo Health

UNKNOWN

Evolution of Lymphocyte Populations Under Biotherapy in Inflammatory Bowel Disease

NCT02693340•Assistance Publique - Hôpitaux de Paris

Summary

This is a monocentric prospective study for the collection of biological samples (blood and biopsies) to be used for in vitro biomarker assay(s) performed to identify predictive markers of response to biological treatments in inflammatory bowel disease (IBD).

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients aged 18 or more.
•Crohn's Disease Diagnosis (CD) or ulcerative colitis (UC) according to defined criteria (ECCO recommendations).
•Active disease as defined by clinical biological and/or morphological assessment.
•Initiation of an anti-Tumor Necrosis Factor (TNF) therapy (Infliximab, Adalimumab, Golimumab) or new biotherapy (Vedolizumab, Ustekinumab) provided in connection with the management of digestive disease.
•Patient (e) have signed and dated consent of the study before undertaking procedures related to the study.

Exclusion Criteria

•Patients under guardianship / curators
•Following Situations
•* Persons unable to understand, read and / or sign an informed consent
•* Patient with the following functions: investigator or co-investigator, research assistant, pharmacist, study coordinator or having any involvement in the study
•* Uncooperative person or potentially non-compliant for the study and its procedures with predictable difficulties regular monitoring of over 1 year.
•* No affiliation to a social security scheme, a universal medical coverage or any similar plan.
•Pregnant or lactating women.

Locations (1)

Gastroenterology department

Paris, Paris, France

Key Dates

Start Date

February 1, 2016

Primary Completion Date

March 1, 2018

Completion Date

March 1, 2020

Last Updated

June 24, 2016

Enrollment

ESTIMATED participants

Conditions

Inflammatory Bowel Disease

Interventions

sampling

BIOLOGICAL

Contacts

Matthieu Allez, MDPhD

CONTACT

+33 1 42 49 95 97 matthieu.allez@aphp.fr

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

NCT06226883

Inflammatory Bowel DiseasesCrohn's Disease

View study

RECRUITINGNA

Impact of Morning Light Therapy in IBD

NCT07207200

Inflammatory Bowel Disease

View study

RECRUITING

Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 24, 2016Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Evolution of Lymphocyte Populations Under Biotherapy in Inflammatory Bowel Disease

Inclusion Criteria

Exclusion Criteria

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

Impact of Morning Light Therapy in IBD

Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)

ALPCO/Calprotectin CLIA Assay: Expected Values of Calprotectin in Healthy Subjects

Prophylactic Dexamethasone Before Infliximab in Moderate-to-Severe IBD

A Phase I Study of HW201877 in Healthy Subjects